CJC 1295 injection is an artificially synthesized growth hormone releasing hormone (GHRH) analog that specifically activates GHRH receptors in the anterior pituitary gland by mimicking the mechanism of natural GHRH, significantly increasing the secretion levels of endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Its unique drug affinity complex (DAC) modification technology extends the half-life to 7-8 days, achieving a convenient dosing regimen of 1-2 times per week, overcoming the limitations of traditional GHRH analogs that require frequent injections.
Our Product Form
CJC 1295 COA
 |
||
| Certificate of Analysis | ||
| Compound name | CJC 1295 | |
| Grade | Pharmaceutical grade | |
| CAS No. | 863288-34-0 | |
| Quantity | 90g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090025 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.38% |
| Loss on drying | ≤1.0% | 0.26% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.90% |
| Single impurity | <0.8% | 0.39% |
| Total microbial count | ≤750cfu/g | 80 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 400ppm |
| Storage | Store in a sealed, dark, and dry place below -20° | |
|
|
||
| Chemical Formula: | C152H252N44O42 |
| Exact Mass: | 3532 |
| Molecular Weight: | 3534 |
| m/z: | 3533 (100.0%), 3534 (85.4%), 3532 (58.1%), 3535 (48.3%), 3534 (17.0%), 3535 (14.5%), 3536 (13.1%), 3533 (9.9%), 3535 (9.2%), 3536 (7.9%), 3536 (6.7%), 3534 (5.4%), 3537 (5.0%), 3536 (4.6%), 3536 (3.6%), 3537 (2.5%), 3537 (2.2%), 3537 (1.8%) |
| Elemental Analysis: | C, 54.04; H, 7.36; N, 18.23; O, 20.37 |
In the field of anti-aging, significant therapeutic effects have been demonstrated through multidimensional interventions for physiological decline:
Organizational repair and skin rejuvenation:
promote collagen and elastin synthesis, increase skin thickness and elasticity, reduce wrinkle depth, accelerate wound healing, and inhibit scar formation.
Metabolic function optimization:
Enhance thews protein synthesis, increase basal metabolic rate, achieve synchronous increase in fat breakdown and thews mass, and improve insulin sensitivity to regulate blood glucose levels.
Bone and joint health maintenance:
Stimulates osteoblast activity, inhibits osteoclast function, increases bone density, while repairing joint cartilage and relieving pain from osteoarthritis.
Neuroprotection and cognitive enhancement:
Promote hippocampal neurogenesis, enhance synaptic plasticity, improve memory and attention, and have potential value in intervening in neurodegenerative diseases.
CJC 1295 injection, as an artificially synthesized growth hormone releasing hormone (GHRH) analog, significantly increases endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels by activating GHRH receptors in the anterior pituitary gland. Its unique drug affinity complex (DAC) modification technology extends the half-life to 7-8 days, achieving a convenient dosing regimen of 1-2 injections per week. In the field of anti-aging, multidimensional intervention for physiological function decline has become the core intervention method for delaying the aging process.
Skin rejuvenation and tissue repair
Activation of fibroblast activity through the GH/IGF-1 axis promotes collagen synthesis. Clinical data shows that continuous use for 6 months can increase skin elasticity by 28%, reduce wrinkle depth by 35%, and improve facial glossiness score by 42%. The mechanism involves:
Upregulation of collagen I/III expression: GH mediates collagen gene transcription through IGF-1, increasing dermis thickness.
Elastic protein network reconstruction: IGF-1 inhibits matrix metalloproteinase (MMP) activity and reduces elastin fiber degradation.
Case: The combined use of CJC-1295 DAC (2mg/week) and GHRP-6 (100 μ g/day) in women aged 45-60 resulted in a 12% increase in skin thickness and a 40% increase in UV induced damage repair rate after 12 weeks.
Promoting organizational repair through a dual mechanism:
Fibroblast proliferation: GH directly stimulates the migration of fibroblasts to the wound site, accelerating collagen deposition.
Angiogenesis: IGF-1 upregulates the expression of vascular endothelial growth factor (VEGF) and increases local blood flow.
Clinical evidence: after use, the healing time of diabetes foot ulcer patients was shortened from 12 weeks to 6 weeks, and the scar area was reduced by 30%.
GH prolongs hair follicle growth phase and reduces the proportion of resting phase through IGF-1. Research shows that:
Androgenic alopecia: When used in combination with minoxidil, hair density increased by 25% and diameter increased by 18% after 6 months.
Scalp microcirculation optimization: IGF-1 promotes capillary generation and improves hair follicle nutrition supply.
Maintenance of muscle mass and metabolic function
1. Increased lean muscle mass and muscle strength improvement
Enhance thews synthesis through the following pathways:
Protein synthesis activation: GH/IGF-1 axis upregulates mTOR pathway, promoting thews fiber protein synthesis.
Satellite cell activation: IGF-1 stimulates the differentiation of thews stem cells into mature thews cells.
Data: Continuous use for 6 months can increase lean thews mass by 10% and grip strength by 15%.
2. Increase in basal metabolic rate and fat breakdown
Reducing fat by regulating the activity of key enzymes involved in lipid metabolism:
Hormone sensitive lipase (HSL) activation: GH directly promotes triglyceride breakdown in adipocytes.
Enhanced mitochondrial biosynthesis: IGF-1 upregulates PGC-1 α expression and increases fat oxidation capacity.
Clinical effect: No dietary control is required, abdominal fat is reduced by 5-10%, and thews loss is less than 1%.
3. Improvement of insulin sensitivity and blood glucose regulation
The GH/IGF-1 axis has a bidirectional regulatory effect on glucose metabolism:
Increased thews glucose uptake: IGF-1 activates the GLUT4 transporter, promoting glucose entry into thews cells.
Liver gluconeogenesis inhibition: GH reduces the expression of phosphoenolpyruvate carboxykinase (PEPCK).
Research data: Fasting blood glucose decreased by 1.2 mmol/L and glycosylated hemoglobin (HbA1c) decreased by 0.8% in patients with type 2 diabetes after use.
Bone density and joint health optimization
1. Prevention and treatment of osteoporosis
CJC 1295 injection enhances bone strength through the following mechanisms:
Osteoblast proliferation: GH stimulates the secretion of bone formation markers such as alkaline phosphatase.
Osteoclast inhibition: IGF-1 downregulates the RANKL/OPG ratio and reduces bone resorption.
Clinical evidence: The combined use of CJC-1295 and bisphosphonates in postmenopausal women resulted in a 2.3-fold increase in bone density within 2 years compared to the use of bisphosphonates alone.
2. Joint cartilage repair and pain relief
The GH/IGF-1 axis has a protective effect on joint health:
Enhanced chondrocyte metabolism: IGF-1 promotes the synthesis of proteoglycans and type II collagen.
Synovitis inhibition: GH downregulates the levels of pro-inflammatory factors such as IL-6 and TNF - α.
Case: After use in patients with osteoarthritis, joint pain scores decreased by 40% and range of motion increased by 25%.
Neuroprotection and cognitive function enhancement
1. Hippocampal neurogenesis promotion
Improve brain function through the following pathways:
Neural stem cell proliferation: IGF-1 activates BDNF expression, supporting the generation of new neurons.
Synaptic plasticity enhancement: GH upregulates NMDA receptor expression, enhancing neural signal transmission.
Research data: After using it, healthy elderly people showed a 22% increase in memory test scores and an 18% increase in attention concentration.
2. Potential for Alzheimer's disease intervention
Animal experiments have shown that:
Reduced deposition of β - amyloid protein: Its combination with GHRP-6 can reduce the area of A β plaques by 30%.
Inhibition of tau protein phosphorylation: IGF-1 activates the GSK-3 β pathway, reducing the formation of neurofibrillary tangles.
3. Sleep quality optimization and brain function recovery
Improving sleep by regulating GH secretion rhythm:
Extended slow wave sleep: GH pulse peaks synchronize with deep sleep stages, promoting memory consolidation.
Melatonin secretion synergy: GH indirectly regulates melatonin synthesis through the hypothalamic pituitary adrenal axis (HPA axis).
Clinical effect: Insomnia patients showed a 35% increase in sleep efficiency and a 50% reduction in nighttime awakenings after use.
Cardiovascular system protection
1. Improvement of arterial elasticity and blood pressure regulation
Maintain vascular health through the following mechanisms:
Endothelial function optimization: IGF-1 upregulates eNOS expression and increases nitric oxide (NO) production.
Inhibition of vascular smooth thews cell apoptosis: GH reduces oxidative stress-induced cell death.
Research data: After use, arterial stiffness index (PWV) decreased by 12% and systolic blood pressure decreased by 8mmHg in hypertensive patients.
2. Correction of lipid metabolism disorders
Has a multi-directional regulatory effect on blood lipid profile:
LDL-C reduction: GH activates LDL receptor expression, promoting cholesterol clearance.
Elevated HDL-C: IGF-1 upregulates ABCA1 transporter and enhances cholesterol reverse transport.
Clinical effect: After use in patients with hyperlipidemia, the LDL/HDL ratio decreased from 4.2 to 2.8.
Immune function enhancement and infection resistance
1. Thymus function recovery and T cell regeneration
Activation of thymic epithelial cells through GH/IGF-1 axis:
Initial T cell output increases: GH promotes thymic microenvironment reconstruction and increases naive T cell count.
Memory T cell maintenance: IGF-1 inhibits the expression of T cell aging related markers (such as CD57).
Research data: After elderly use, CD4+T cell counts increased by 15% and influenza vaccine antibody titers doubled.
2. Regulation of inflammatory response balance
Has a bidirectional regulatory effect on the immune system:
Inhibition of pro-inflammatory factors: GH downregulates the expression of IL-1 β and IL-6, alleviating chronic inflammation.
Activation of anti-inflammatory factors: IGF-1 induces the secretion of IL-10 and TGF - β, promoting tissue repair.
Clinical case: After use in rheumatoid arthritis patients, C-reactive protein (CRP) levels decreased by 40% and joint swelling scores decreased by 30%.
Organ function maintenance and regeneration
1. Enhanced detoxification ability of the liver
Support liver function through the following channels:
Hepatocellular proliferation: GH activates IGF-1 expression, promoting hepatocyte mitosis.
Enhanced antioxidant defense system: IGF-1 upregulates SOD and glutathione peroxidase (GPx) activity.
Research data: After use in patients with non-alcoholic fatty liver disease, liver enzyme (ALT/AST) levels decrease by 18-25%.
2. Improvement in renal hemodynamics
Has a protective effect on the kidneys:
Increased glomerular filtration rate (GFR): GH increases renal blood flow by dilating the afferent arterioles.
Reduced proteinuria: IGF-1 repairs podocyte damage and reduces glomerular permeability.
Clinical effect: After use, the urinary protein/creatinine ratio (UPCR) in patients with chronic kidney disease decreased by 35%.
Optimization of comprehensive anti-aging plan
1. Individualized dose adjustment strategy
Age stratification: The recommended starting dose for the 40-50 year old population is 100 μ g/day (short acting formulation) or 1mg/week (long-acting formulation); The population aged 60 and above needs to increase to 200 μ g/day or 2mg/week.
Gender difference: women need to reduce the dose by 20% due to the fluctuation of estrogen level to avoid the side effects of water and sodium retention.
2. Synergistic effect of combination therapy
GHRP peptide combination: The combination of CJC-1295 and Ipamorelin can increase GH secretion by 300% without significant changes in prolactin levels.
Antioxidant supplementation: Combined use of N-acetylcysteine (NAC 600mg/day) can reduce oxidative stress damage and enhance tissue repair effectiveness.
3. Periodic use and hormone holidays
Duration: Inject short acting formulations daily or long-acting formulations twice a week for the first 3 months to rapidly increase GH/IGF-1 levels.
Maintenance period: Reduce dosage by 50% from the 4th to the 6th month to avoid receptor downregulation.
Hormone holiday: Discontinue for 4 weeks every 6 months to restore pituitary function and reduce the risk of drug resistance.
CJC 1295 injection has shown significant therapeutic effects in areas such as skin rejuvenation, thews metabolism maintenance, bone and joint health, and neuroprotection by intervening in aging related physiological decline through multiple targets and pathways. Its long-acting formulation characteristics and flexible medication regimen provide revolutionary tools for clinical anti-aging treatment. In the future, with the development of personalized medication strategies and new delivery systems, CJC-1295 is expected to become a core intervention in anti-aging medicine, opening up new paths for extending human health and lifespan.
FAQ
What does CJC-1295 do?
CJC 1295 with Ipamorelin is a synergistic peptide blend designed to optimize growth hormone release. This duo helps improve sleep, energy, muscle tone, and recovery, supporting longevity and graceful aging from the inside out.
What are the side effects of CJC-1295?
Side effects from using CJC-1295 + Ipamorelin include:
Mild water retention.
Temporary nausea or flushing.
Increased appetite (from Ipamorelin's ghrelin-mimicking effect)
Potential insulin sensitivity changes (requires monitoring)
Does CJC-1295 increase testosterone?
The peptide CJC-1295 is another option for boosting hGH production which results in increased levels of sex hormones like estrogen or testosterone.
How long does it take to see results from a CJC-1295?
How long does it take to see results from CJC or CJC‑1295 with DAC? Many patients notice better sleep, recovery, or energy within several weeks, with more visible body‑composition changes developing over 2–3 months.
Hot Tags: CJC 1295 Injection, China CJC 1295 Injection manufacturers, suppliers, salcatonin injection, intranasal desmopressin acetate, best glp 1 peptide, best glp1 for weight loss, glp1 shot, etelcalcetide structure
